KCNE4

KCNE4 is a single-transmembrane ancillary (β) subunit that broadly inhibits voltage-gated potassium channels, shaping K⁺ current properties in cardiac, vascular, renal, and immune cells. It suppresses KCNQ1 current through biophysical gating modulation at the plasma membrane—not by reducing surface expression—with its C-terminal domain necessary and sufficient for inhibition and its transmembrane domain playing a cooperative role (PMID:12096056, PMID:19029186). KCNE4 also inhibits Kv1.3 in leukocytes by retaining the channel in the ER through a juxtamembrane tetraleucine motif that masks Kv1.3's forward-trafficking signal and provides an intrinsic ER retention signal; this motif serves as a competitive binding platform for Kv1.3, Ca²⁺/calmodulin, and KCNE4 dimers, coupling CaM-dependent COP-II trafficking to channel surface abundance (PMID:27802162, PMID:30969795, PMID:34234241). Germline Kcne4 deletion in mice reveals testosterone-dependent roles in cardiac repolarization and arrhythmia susceptibility as well as vascular smooth muscle tone via regulation of Kv7.4 surface expression (PMID:29844497, PMID:26503181, PMID:27710966).

1. 2002 High

   The first functional identity of KCNE4 was established: it is an inhibitory β-subunit of KCNQ1, resolving whether this orphan KCNE family member modulates any known K⁺ channel.

   Evidence Two-electrode voltage clamp in Xenopus oocytes and patch clamp in CHO-K1 cells with delayed mRNA expression and immunocytochemistry

   PMID:12096056

   Open questions at the time

   • Mechanism of inhibition (gating vs. trafficking) not fully resolved
   • No native tissue context established
   • No structural information
2. 2003 High

   KCNE4's partner range was expanded beyond KCNQ1 to Kv1.1 and Kv1.3 (but not Kv1.2, Kv1.4, Kv1.5, Kv4.3), establishing subunit selectivity among Shaker-family channels.

   Evidence Electrophysiology in Xenopus oocytes and HEK293 cells with confocal microscopy and Western blotting

   PMID:12944270

   Open questions at the time

   • Molecular determinants of selectivity among Kv1 subtypes unknown
   • No loss-of-function data in native tissues
3. 2007 Medium

   A disease-relevant polymorphism (E145D) was shown to convert KCNE4 from a KCNQ1 inhibitor to an activator, linking KCNE4 to atrial fibrillation susceptibility.

   Evidence Site-directed mutagenesis with patch clamp in CHO-K1 cells

   PMID:17335661

   Open questions at the time

   • Single heterologous system study
   • No patient functional data or animal model confirmation
   • Structural basis of gain-of-function unknown
4. 2008 High

   Three advances defined the molecular architecture and domain requirements of KCNE4 inhibition: KCNE4 forms trimeric complexes with KCNE1/KCNQ1 without reducing surface expression, the C-terminal domain is necessary and sufficient for KCNQ1 inhibition, and KCNE4 associates with BK channels in renal cells to modulate Ca²⁺-dependent gating.

   Evidence Co-immunoprecipitation, cell surface biotinylation, chimera mutagenesis, immunohistochemistry in kidney, and electrophysiology

   PMID:18279388 PMID:18463315 PMID:19029186

   Open questions at the time

   • Atomic-level structure of any KCNE4–channel complex not determined
   • BK modulation not confirmed by genetic loss-of-function
   • Whether trimeric stoichiometry is obligatory in vivo unknown
5. 2009 High

   KCNE4 was established as the physiologically relevant inhibitor of Kv1.3 in leukocytes, acting through ER retention and lipid raft exclusion rather than purely gating modulation, and its expression is dynamically regulated by immune activation.

   Evidence Electrophysiology, co-immunoprecipitation, confocal microscopy, lipid raft fractionation, and RT-PCR in macrophages and leukocyte cell lines

   PMID:19773357

   Open questions at the time

   • Molecular determinants of ER retention not yet mapped
   • In vivo immune phenotype of KCNE4 deletion not tested
6. 2010 High

   A Ca²⁺/calmodulin-dependent mechanism was identified for KCNE4's inhibitory activity: CaM binds the juxtamembrane tetraleucine motif in KCNE4's C-terminus, and disruption of this interaction impairs KCNQ1 inhibition. Separately, KCNE4 was shown to co-localize with Kv4.2 in cardiac transverse tubules and form ternary complexes with KChIP2.

   Evidence Co-immunoprecipitation, mutagenesis, Ca²⁺ chelation, electrophysiology; immunofluorescence in cardiac myocytes with patch clamp and co-IP in tsA201 cells

   PMID:20498229 PMID:21118809

   Open questions at the time

   • Whether CaM is bound constitutively or recruited dynamically in native cells unknown
   • Physiological role of KCNE4-Kv4.2-KChIP2 ternary complex not tested by loss-of-function
7. 2015 High

   Genetic loss-of-function studies in mice established that KCNE4 is required for sex-specific cardiac K⁺ current magnitude (Ito,f and IK,slow1) under testosterone control, and for Kv7.4-dependent vascular tone in mesenteric arteries.

   Evidence Germline Kcne4 knockout with patch clamp in cardiomyocytes, castration/DHT implants; morpholino knockdown in mesenteric arteries with myography and proximity ligation assay

   PMID:26399785 PMID:26503181

   Open questions at the time

   • Whether KCNE4 regulation of Kv1.5 underlies IK,slow1 change was shown only in heterologous expression
   • How testosterone regulates Kcne4 transcription is undefined
8. 2016 High

   The molecular mechanism of Kv1.3 retention was dissected: KCNE4 masks the Kv1.3 YMVIEE forward-trafficking motif and contributes its own ER retention signal, operating through dual additive mechanisms. Concurrently, novel N-terminally extended KCNE4 isoforms with altered regulatory properties were identified in human tissues, and Kv4.3 was added as a target in human atrium.

   Evidence Truncation/domain-swap mutagenesis with electrophysiology and confocal microscopy; molecular cloning with oocyte electrophysiology; germline knockout myography

   PMID:27162025 PMID:27710966 PMID:27802162 PMID:27922120

   Open questions at the time

   • Whether the long isoform predominates in vivo is unresolved
   • How dual retention signals are coordinated with COP-II trafficking unknown
9. 2018 High

   KCNE4 deletion was linked to sex-specific cardiac arrhythmia: aged Kcne4⁻/⁻ males show QT prolongation and ischemia/reperfusion-induced ventricular tachyarrhythmias due to testosterone-dependent impairment of RISK/SAFE cardioprotective pathways.

   Evidence Germline knockout, ECG telemetry, ischemia/reperfusion surgery, phospho-protein Western blot, castration experiments

   PMID:29844497

   Open questions at the time

   • How KCNE4 influences RISK/SAFE signaling mechanistically is unclear
   • Human translational data for arrhythmia link absent
10. 2019 High

    The tetraleucine motif was shown to be the direct binding site for Kv1.3 and Ca²⁺/CaM in a competitive manner, unifying the trafficking-control and CaM-dependent regulatory mechanisms into a single molecular switch.

    Evidence Mutagenesis, co-immunoprecipitation, FRET, in silico structural modelling, electrophysiology

    PMID:30969795

    Open questions at the time

    • No experimentally determined high-resolution structure of the KCNE4-Kv1.3 complex
    • In vivo relevance of competitive CaM/Kv1.3 binding not tested
11. 2020 Medium

    Variable stoichiometry of KCNE4 association with Kv1.3 (up to 4:4) was demonstrated, with distinct functional consequences at each occupancy level, and KCNE4 was confirmed to interact with Kv7.4 and Kv7.5 by FRET.

    Evidence Tandem-linked concatemer constructs with electrophysiology and flow cytometry; co-immunoprecipitation and FRET with patch clamp in HEK293 cells

    PMID:32370164 PMID:33093272

    Open questions at the time

    • Native stoichiometry in leukocytes or cardiac cells not determined
    • Kv7.5 regulation not confirmed in native tissue
12. 2021 High

    KCNE4 was found to uniquely dimerize among KCNE family members via its tetraleucine motif in a CaM/Ca²⁺-dependent manner, controlling its own ER-to-surface trafficking via COP-II; this established the tetraleucine motif as a three-way competitive platform (Kv1.3, CaM, and KCNE4 dimerization). Functionally, KCNE4 was shown to control T cell activation and dendritic cell proliferation through Kv1.3 regulation at the immunological synapse.

    Evidence FRET, co-immunoprecipitation, Ca²⁺ chelation, confocal microscopy, COP-II inhibitor experiments; overexpression/ablation in Jurkat T cells and CY15 dendritic cells with functional immune readouts

    PMID:34234241 PMID:34272451

    Open questions at the time

    • Crystal or cryo-EM structure of KCNE4 dimer not available
    • In vivo immune phenotype of KCNE4 knockout not reported
    • Whether dimerization also regulates KCNE4 association with non-Kv1.3 partners is untested
13. 2024 Medium

    Purified KCNE4 was reconstituted in lipid bilayers, confirming its predicted single-transmembrane topology by EPR, representing the first biophysical characterization of KCNE4 protein structure outside a channel complex.

    Evidence Recombinant expression and purification from E. coli, CD spectroscopy, CW-EPR power saturation in lipid bilayers

    PMID:39780724

    Open questions at the time

    • No high-resolution structure yet
    • Reconstitution with a channel partner not performed
    • Only topology confirmed, not tertiary fold details

• Major unresolved questions include the high-resolution structure of KCNE4 alone and in complex with any channel partner, the in vivo immune phenotype of KCNE4 genetic deletion, the mechanism by which KCNE4 influences RISK/SAFE cardioprotective signaling, and whether the long N-terminal isoform is the predominant functional form in human tissues.
• No experimentally determined atomic structure
• No KCNE4 knockout immune phenotype reported in vivo
• Human genetic validation for cardiac arrhythmia remains limited